TGFB1 and cancer: Emerging evidence indicates that TGF-β pathway gets activated in response to treatment with DNA-damaging agents, such as doxorubicin and etoposide, in cancer patients as well as in cell lines and can affect the clinical outcomes of patients undergoing chemotherapy [39,42].